GlassScriptPhysician profile
James T Brown
NPI 1326082298
$850.66
in general payments reported to CMS, 2019-2025
12 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.74 · 2020: $60.92 · 2021: $141 · 2022: $140 · 2023: $96.56 · 2024: $152 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.99 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $94.73 | 2022-2024 | Krystexxa, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $76.83 | 2022-2024 | |
| Dexcom, INC. | $63.15 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $45.02 | 2024-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $33.32 | 2024 | Farxiga, Airsupra |
| Edwards Lifesciences Corporation | $32.42 | 2021 | |
| Esperion Therapeutics, INC. | $18.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.27 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $12.45 | 2021 | |
| Abbvie INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.